Randomized clinical trial france DMLA2: Effect of trimetazidine on exudative and nonexudative age-related macular degeneration

Retina

Volumn 32, Issue 4, 2012, Pages 834-843

  Cohen, Salomon Yves ^a   Bourgeois, Hubert ^b   Corbe, Christian ^c   Chaine, Gilles ^d   Espinasse Berrod, Marie Andrée ^e   Garcia Sanchez, Julian ^f   Gaudric, Alain ^g   Hullo, Alain ^h   Leys, Anita ⁱ   Soubrane, Gisèle ^j   Sahel, Joséa ^k  

^a Ophthalmic Center for Imaging and Laser   (France)

^b University of Paris Descartes   (France)

^c Invalids Hospital   (France)

^d AVICENNE HOSPITAL   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^g HÔPITAL LARIBOISIÈRE   (France)

^h CENTRE HOSPITALIER LYON SUD   (France)

ⁱ UNIVERSITY OF LEUVEN   (Belgium)

^j University Eye Clinic   (France)

^k CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

more..

Author keywords

age related macular degeneration; choroidal neovascularization; geographic atrophy; randomized clinical trial; trimetazidine

Indexed keywords

PLACEBO; TRIMETAZIDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; FOLLOW UP; FRANCE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PIGMENT EPITHELIUM; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; STATISTICAL SIGNIFICANCE; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; BELGIUM; CHOROIDAL NEOVASCULARIZATION; DOUBLE-BLIND METHOD; EXUDATES AND TRANSUDATES; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; SPAIN; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 84859106325     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31822058a3     Document Type: Article

References (38)

1. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988;32:375-413.
2. Friedman DS, O'Colmain BJ, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572. (Pubitemid 38456293)
3. Tomany SC, Wand JJ, Van Leuwen R, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004;111:1280-1287. (Pubitemid 38844822)
4. Fine SL, Berger JW, Maguire MG, Ho AC. Age related macular degeneration. N Engl J Med 2000;342:483-492.
5. Seddon J, Chen C. Epidemiology of age-related macular degeneration. In: Ryan SJ, ed. Retina, Vol. 2. Medical Retina, 4th ed., St Louis, MO; Mosby, 2004.
6. Beatty S, Koh H-H, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000;45:115-134.
7. Bonne C, Muller A. Rôle dustress oxydant dans la dégénérescence maculaire liée à l'âge. J Fr Ophtalmol 2000;23:835-840.
8. Chaine G, Hullo A, Sahel J, et al. Case-control study of risk factors for age related macular degeneration. Br J Ophthalmol 1998;82:996-1002. (Pubitemid 28451268)
9. Khan JC, Thurlby DA, Shahid H, et al. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic and choroidal neovascularization. Br J Ophthalmol 2006;90:75-80. (Pubitemid 43029901)
10. Klaver CC, Wolfs RC, Assink JJ, et al. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol 1998;116:1646-1651. (Pubitemid 29001964)
11. Klein R, Peto T, Bird A, van Newkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004; 137:486-495.
12. Souied EH, Ducroq D, Rozet JM, et al. ABCR gene analysis infamilial exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 2000;41:244-247. (Pubitemid 30036573)
13. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration. Pooled findings from three continents. Ophthalmology 2001;108:697-704.
14. Soubrane G. Les DMLAs. Paris, France: Masson Elsevier; 2007:638 p.
15. Piguet B, Palmvang IB, Chisholm IH, Minassian D. Evolution of age-related macular degeneration with choroidal perfusion abnormality. Am J Ophthalmol 1992;113:657-663.
16. Pournaras CJ, Logean E, Riva CE, et al. Regulation of subfoveal choroidal blood flow in age-related macular degeneration. Invest Ophthalmol Vis Sci 2006;47:1581-1586. (Pubitemid 46780768)
17. Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol 1999;6:125-143. (Pubitemid 29391400)
18. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high dose supplementation with vitamin C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch Ophthalmol 2001;119:1417-1436.
19. Age-Related Eye Disease Study Research Group. The relationship of dietary carotenoids and vitamin A, E and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol 2007;125:1225-1232.
20. Klein ML, Ferris FL III, Armstrong J, et al. Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology 2008;115:1026-1031. (Pubitemid 351749691)
21. Richer S, Stiles W, Statkute L, et al. Double-masked, placebocontrolled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004;75:216-230. (Pubitemid 39208022)
22. Klein R, Davis MD, Magli YL, et al. The Wisconsin agerelated maculopathy grading system. Ophthalmology 1991;98: 1128-1134.
23. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 1995; 39:367-374.
24. Cox DR, Oakes D.Analysis of Survival Data. London, UK: Chapman and Hall; 1984.
25. Quantin C, Asselain B, Moreau T. Le modèle deCox: limites et extension. Rev Epidémiol Santé Publique 1990;38:341-356.
26. Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol 1993;111:1189-1199.
27. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Arch Ophthalmol 1997;115:741-747.
28. Age-Related Eye Disease Study Research Group. The agerelated eye disease study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005; 123:1484-1498.
29. Age-Related Eye Disease Study Research Group. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 2005;123:1570-1574.
30. Maguire MG, Alexander J, Fine SL; the Complication of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Characteristics of choroidal neovascularization in the complications of age-related macular degeneration prevention trial. Ophthalmology 2008;115:1468-1473.
31. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642. (Pubitemid 15204559)
32. Sunness JS. The natural history of geographic atrophy, the advanced atrophic for of age-related macular degeneration. Mol Vision 1999;5:25. Available at: http://www.molvis.org/ molvis/v5/p25. Accessed November 3, 2009.
33. Sarks SH. Council lecture. Drusen and their relationship to senile macular degeneration. Aust J Ophthalmol 1980;8: 117-130. (Pubitemid 10014380)
34. Complication of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration prevention trial. Ophthalmology 2008;115:1474-1479.
35. Delbarre B, Delbarre G, Calinon F. Action of trimetazidine on retina of gerbils after ischemia reperfusion insult: Determination of ·OH, amino acids, and electroretinogram. Annals N Y Acad Sci 1994;738:334-340.
36. Mohand-Said S, Jacquet A, Lucien A, et al. Protective effect of trimetazidine in a model of ischemia-reperfusion in the rat retina. Ophalmic Res 2002;34:300-305. (Pubitemid 36157314)
37. Özden S, Kildaci B, Muftuoglu S, Cakari N. Effect of trimetazidine on retinal ischemia/reperfusion injury in rats. Ophthalmologica 2001;215:309-317. (Pubitemid 32588892)
38. Payet O, d'Aldin C, Maurin L, et al. Anti-excitotoxic activity of trimetazidine in the retina. J Ocular Pharmacol Ther 2004; 20:85-92.